Aimmune CFO Warren DeSouza leaves

  • Signs for push-out forces
  • After two years on the job
  • No successor named

( — Brisbane, California, December 14, 2016 — Warren DeSouza, finance chief of Aimmune, leaves. His departure is made public at an early stage. As announced by Aimmune Therapeutics, Inc. in a regulatory filing published on Wednesday, December 14, 2016, Warren L. DeSouza leaves the post as Chief Financial Officer at the clinical-stage biopharmaceutical company in a surprising move after two years on the job, effective April 16, 2017.

No company wants a CFO to flame out in the first years.

Aimmune did not name a replacement.

“To pursue other opportunities”

DeSouza’s move is explained as follows. Aimmune said: “On December 8, 2016, Warren DeSouza, the Chief Financial Officer of Aimmune Therapeutics, Inc., a Delaware corporation …, notified the Company of his intention to leave his position of Chief Financial Officer of the Company on April 16, 2017 to pursue other opportunities.”

The phrase “to pursue other opportunities” is often used in corporate announcements and opens the door to speculation.

Precise information about the future plans of DeSouza was not immediately available.

Chaired by Mark McDade

Aimmune Therapeutics, Inc. is chaired by Mark McDade.

Mark McDade is Chairman of the Aimmune Board of Directors and Executive Vice President and Chief Operating Officer of UCB, a global biopharmaceutical company focusing on neurology and immunology treatment and research.

Stephen G. Dilly serves as CEO of Aimmune Therapeutics, Inc. Dilly has been the Chief Executive Officer of Aimmune Therapeutics, Inc. since April 2014.

On the job as CFO since 2015

DeSouza has been the Chief Financial Officer of Aimmune Therapeutics, Inc., (formerly Allergen Research Corporation, ARC) since April 2015.

DeSouza has 25 years of combined experience in biotechnology finance and audit-assurance consulting.

He was most recently Vice President, Finance, at Onyx Pharmaceuticals. In nine years with Onyx, he led accounting, SEC reporting, purchasing, tax, treasury, and risk management, among other responsibilities.

Prior to Onyx, DeSouza held a senior role in assurance at Deloitte & Touche LLP.

DeSouza began his career with more than a decade in assurance at Arthur Andersen LLP, where he managed client accounts, led audits and oversaw SEC filings.

DeSouza earned a bachelor’s of Business Administration degree from the University of Notre Dame.


Generally speaking, when a top manager announces to step aside with no successor available, it’s a sign that the change was unplanned and too early.

Generally speaking, potential causes for an unplanned management change can be, among others, disagreement, health reasons, urgent family reasons or surprising new career opportunities.

Signs for push-out forces

It is not completely certain what forces eventually triggered Warren L. DeSouza’s move.

The Push-out Score™ determined by suggests that push-out forces may have contributed to the management change.

Read the full story in the report 47.2016 ($).